CPT codes have been created for reporting of immunizations for the novel coronavirus (SARS-CoV-2, also known as COVID-19). These CPT codes are unique for each coronavirus vaccine as well as administration codes unique to each such vaccine. The new CPT codes clinically distinguish each coronavirus vaccine for better tracking, reporting and analysis that supports data-driven planning and allocation.

Summary of the SARS-CoV-2 related CPT codes:

CPT codes that have been approved for the CPT code set related to SARS-CoV-2.

Oct. 27, 2021: Accepted a Category I code to report SARS-CoV-2 vaccine and immunization administration codes. Code 0034A will be used to report Janssen booster vaccine and immunization administration. Appendix Q has been updated to reflect this addition. This code was published on Oct. 27, 2021 and was effective Oct. 20, 2021.

Oct. 6, 2021: Accepted three Category I codes to report SARS-CoV-2 vaccine and immunization administration codes. Codes 91307, 0071A, and 0072A are used to report Pfizer COVID-19 vaccine and immunization administration for the tris-sucrose pediatric (i.e., 5 through 11 years of age) dosage formulation. These codes were published on Oct. 6, 2021. The Pfizer pediatric dose was effective on Oct. 29, 2021. As with all the CPT codes related to COVID-19 vaccines, the effective dates coincide with the emergency use authorization issued by U.S. Food and Drug Administration (FDA). .

Sept. 3, 2021: Accepted eight Category I codes to report SARS-CoV-2 vaccine and immunization administration codes. Codes 91305, 0051A, 0052A and 0053A are used to report Pfizer COVID-19 vaccine and immunization administration for the tris-sucrose formulation. Codes 0004A and 0054A are used to report Pfizer COVID-19 immunization administration booster doses for both available formulations. Codes 91306 and 0064A are used to report Moderna COVID-19 vaccine and immunization administration booster doses. Appendix Q has been updated to reflect these additions. These codes were published on Sept. 3, 2021. The Pfizer booster dose was effective on Sept. 22. As with all the CPT codes related to COVID-19 vaccines, the effective dates coincide with the emergency use authorization issued by U.S. Food and Drug Administration (FDA). The Moderna COVID-19 vaccine and immunization administration booster doses are effective as of Oct. 20, 2021.

Aug. 16, 2021: Accepted addition of one administration code 0013A to report Moderna third dose. Appendix Q has been updated to reflect this addition. This code was published on Aug. 16, 2021 and this code (0013A) is effective for Emergency Use Authorization as of Aug. 12, 2021.

July 30, 2021: Accepted addition of one administration code 0003A to report Pfizer-BioNTech third dose. Appendix Q has been updated to reflect this addition. This code was published on July 30, 2021 and this code (0003A) is effective for Emergency Use Authorization as of Aug. 12, 2021.

May 4, 2021: Accepted addition of one Category I code to report SARS-CoV-2 vaccine and two immunization administration codes. Codes 91304, 0041A, 0042A are used to report the Novavax COVID-19 vaccine, Appendix Q has been updated to reflect these additions. These codes were published on May 4, 2021 and will be effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration.

Jan. 19, 2021: Accepted addition of one Category I code to report SARS-CoV-2 vaccine and immunization administration codes. Codes 91303, 0031A are used to report the Janssen COVID-19 vaccine, Appendix Q has been updated to reflect these additions. These codes were published on January 19, 2021 and will be effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration.

Dec. 17, 2020: Accepted addition of two Category I codes to report SARS-CoV-2 vaccine and immunization administration codes. Codes 91302, 0021A and 0022A are used to report the AstraZeneca COVID-19 vaccine and updated Appendix Q to reflect these additions. These codes were published on December 17, 2020 and will be effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration.

Nov. 10, 2020: Accepted addition of codes addition of six Category I codes to report SARS-CoV-2 vaccine and immunization administration codes. Codes 91300, 0001A and 0002A are used to report the Pfizer-BioNTech. COVID-19 vaccine and 91301, 0011A and 0012A are used to report the Moderna COVID-19 vaccine. Also, new and revised guidelines, parenthetical notes, and a new Appendix Q were added. These codes were published on November 10, 2020 and will be effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration.

Accepted addition of code 87428 for reporting multiplex viral pathogen panel using antigen immunoassay technique for SARS-CoV-2 testing along with influenza A and influenza B.

Accepted addition of code 87636 for reporting combined respiratory virus multiplex testing for either SARS-CoV-2 with Influenza A&B, code 87637 for combined respiratory virus multiplex testing for either SARS-CoV-2 with Influenza A&B and RSV and 87811for antigen detection of SARS-CoV-2 by direct optical (i.e., visual) observation. Two new PLA codes (0240U and 0241U) were accepted for detection of SARS-CoV-2, Influenza A and Influenza B; code 0241U also detects RSV. Additionally, Immunology guidelines were also revised, along with codes 87301, 87802 and their subsidiary codes.

Accepted addition of code 99072 for the additional supplies and clinical staff time required to mitigate transmission of respiratory infectious disease while providing evaluation, treatment, or procedural services during a public health emergency, as defined by law. In addition, one code, 86413, was created for reporting quantitative antibody detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Aug. 10, 2020: Accepted addition of codes 86408 for reporting coronavirus 2 (SARS-CoV-2) neutralizing antibody screen and 86409 for reporting coronavirus 2 (SARS-CoV-2) neutralizing antibody titer. In addition, two new PLA codes (0225U and 0226U) were accepted for detection of SARS-CoV-2. These new codes are effective Aug. 10, 2020.
Accepted addition of code 87426 to report infectious agent antigen detection by immunoassay technique of SARS-CoV and SARS-CoV-2. In addition, two new PLA codes (0223U and 0224U) were accepted for detection of SARS-CoV-2.

May 20, 2020: Accepted addition of PLA code 0202U to report the BioFire® Respiratory Panel 2.1 (RP2.1) test. The new code was effective May 20, 2020.

April 10, 2020: Accepted revision of code 86318 to report immunoassay for infectious agent antibody(ies) and to be a parent to 86328; addition of code 86328 to report single step antibody testing for severe acute respiratory syndrome coronavirus 2; addition of child code 86769 to report multiple-step antibody testing for severe acute respiratory syndrome coronavirus 2; and revision of the Immunology guidelines. The new codes and revision were effective April 10, 2020.

March 13, 2020: Accepted addition of code 87635 to report infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique. The new code was effective March 13, 2020.

For more information, visit: https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-coding-and-guidance